TY - JOUR
T1 - Impact of Managing Provider Type on Severe Aortic Stenosis Management and Mortality
AU - Pellikka, Patricia A.
AU - Padang, Ratnasari
AU - Scott, Christopher G.
AU - Murphy, Shannon M.E.
AU - Fabunmi, Rosalind
AU - Thaden, Jeremy J.
N1 - Funding Information:
This study was funded by Edwards Lifesciences, Inc. Additional funding to support statistical analysis was available to Dr Pellikka as the Betty Knight Scripps Professor of Cardiovascular Disease Clinical Research, Mayo Clinic.
Funding Information:
Patricia Pellikka reports research support funding (paid to Mayo Clinic) from the American Society of Echocardiography Foundation, GE Healthcare, Ultromics, and Lantheus. Ratnasari Padang and Christopher Scott have no disclosures to report. Shannon Murphy—reports employment at Edwards Lifesciences and current equity holdings. Rosalind Fabunmi— reports employment at Edwards Lifesciences and current equity holdings. Jeremy Thaden— reports consulting fees (paid to Mayo Clinic) from Medtronic.
Publisher Copyright:
© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
PY - 2022/7/5
Y1 - 2022/7/5
N2 - BACKGROUND: Many patients with symptomatic severe aortic stenosis do not undergo aortic valve replacement (AVR) despite clinical guidelines. This study analyzed the association of managing provider type with cardiac specialist follow-up, AVR, and mortality for patients with newly diagnosed severe aortic stenosis (sAS). METHODS AND RESULTS: We identified adults with newly diagnosed sAS per echocardiography performed between January 2017 and March 2019 using Optum electronic health record data. We then selected from those meeting all eligibility criteria patients managed by a primary care provider (n=1707 [25%]) or cardiac specialist (n=5039 [75%]). We evaluated the association of managing provider type with cardiac specialist follow-up, AVR, and mortality, as well as the independent association of cardiac specialist follow-up and AVR with mortality, within 1 year of echocardiography detecting sAS. A subgroup analysis was limited to patients with symptomatic sAS. Patient characteristics and comorbidities at baseline were used for covariateadjusted cause-specific and multivariable Cox proportional hazard models assessing group differences in outcomes by managing provider type. An adjusted Cox proportional hazard model with additional time-dependent covariates for follow-up and AVR was used to assess these practices’ association with mortality. Within 1 year of echocardiography detecting sAS, data revealed that primary care provider management was associated with lower rates of cardiac specialist follow-up (hazard ratio [HR], 0.47 [95% CI, 0.43–0.50], P<0.0001) and AVR (HR, 0.58 [95% CI, 0.53–0.64], P<0.0001) and with higher 1-year mortality (HR, 1.45 [95% CI, 1.26–1.66], P<0.0001). Cardiac specialist follow-up and AVR were independently associated with lower mortality (follow-up: HR, 0.55 [95% CI, 0.48–0.63], P<0.0001; AVR: HR, 0.70 [95% CI, 0.60–0.83], P<0.0001). Results were similar for patients with symptomatic sAS. All analyses were adjusted for baseline patient characteristics and comorbidities. CONCLUSIONS: For patients newly diagnosed with sAS, we observed differences in rates of cardiac specialist follow-up and AVR and risk of mortality between primary care provider-versus cardiologist-managed patients with sAS. In addition, a lower likelihood of receiving follow-up and AVR was independently associated with higher mortality.
AB - BACKGROUND: Many patients with symptomatic severe aortic stenosis do not undergo aortic valve replacement (AVR) despite clinical guidelines. This study analyzed the association of managing provider type with cardiac specialist follow-up, AVR, and mortality for patients with newly diagnosed severe aortic stenosis (sAS). METHODS AND RESULTS: We identified adults with newly diagnosed sAS per echocardiography performed between January 2017 and March 2019 using Optum electronic health record data. We then selected from those meeting all eligibility criteria patients managed by a primary care provider (n=1707 [25%]) or cardiac specialist (n=5039 [75%]). We evaluated the association of managing provider type with cardiac specialist follow-up, AVR, and mortality, as well as the independent association of cardiac specialist follow-up and AVR with mortality, within 1 year of echocardiography detecting sAS. A subgroup analysis was limited to patients with symptomatic sAS. Patient characteristics and comorbidities at baseline were used for covariateadjusted cause-specific and multivariable Cox proportional hazard models assessing group differences in outcomes by managing provider type. An adjusted Cox proportional hazard model with additional time-dependent covariates for follow-up and AVR was used to assess these practices’ association with mortality. Within 1 year of echocardiography detecting sAS, data revealed that primary care provider management was associated with lower rates of cardiac specialist follow-up (hazard ratio [HR], 0.47 [95% CI, 0.43–0.50], P<0.0001) and AVR (HR, 0.58 [95% CI, 0.53–0.64], P<0.0001) and with higher 1-year mortality (HR, 1.45 [95% CI, 1.26–1.66], P<0.0001). Cardiac specialist follow-up and AVR were independently associated with lower mortality (follow-up: HR, 0.55 [95% CI, 0.48–0.63], P<0.0001; AVR: HR, 0.70 [95% CI, 0.60–0.83], P<0.0001). Results were similar for patients with symptomatic sAS. All analyses were adjusted for baseline patient characteristics and comorbidities. CONCLUSIONS: For patients newly diagnosed with sAS, we observed differences in rates of cardiac specialist follow-up and AVR and risk of mortality between primary care provider-versus cardiologist-managed patients with sAS. In addition, a lower likelihood of receiving follow-up and AVR was independently associated with higher mortality.
KW - TAVR
KW - aortic stenosis
KW - aortic valve
KW - echocardiography
KW - valve disease
UR - http://www.scopus.com/inward/record.url?scp=85133932286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133932286&partnerID=8YFLogxK
U2 - 10.1161/JAHA.121.025164
DO - 10.1161/JAHA.121.025164
M3 - Article
C2 - 35766279
AN - SCOPUS:85133932286
SN - 2047-9980
VL - 11
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 13
M1 - e025164
ER -